36 reports

  • diabetes and obesity are significant secondary causes of dyslipidemia. In addition to
  • 4.1 DISEASE BACKGROUND

A genetic basis for coronary artery disease.

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

genetic causes of dyslipidemia) ##. ##. ## Secondary Causes (lifestyle factors) ##. ## Dyslipidemia Diagnostics ##. ##. ## Serum Lipid Profile Measurement (total cholesterol, HDL, LDL, VLDL, etc. ) ##. ##. ## Other Tests (lipoprotein-A tests, apo lipoprotein B tests, etc. ) ##. ##. ## Secondary Causes Screening a

  • Cholesterol
  • Therapy
  • World
  • Forecast
  • Market Size
  • Risk Factors and Comorbidities for Dyslipidemia
  • 2.2 RISK FACTORS AND COMORBIDITIES

Its prevalence in the population is sensitive to founder effects, which consists of the loss of normal genetic variation in populations that were initially established from a very small number of individuals, particularly when consanguineous marriages are common.

  • Cholesterol
  • China
  • Germany
  • Japan
  • Forecast

Statins are also known to intensify mitochondrial or metabolic vulnerability such as thyroid diseases, metabolic syndrome factors, and genetic mutations linked to mitochondrial dysfunction.

  • Cholesterol
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 3.1.1 ETIOLOGY
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 2.1 CATALYST

A genetic basis for coronary artery disease.

  • Cholesterol
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.

In its broadest sense, the term ' nutraceutical' may cover a range of products from isolated nutrients, dietary supplements and diets to genetically engineered designer foods, herbal products and processed foods (Andlauer 2002).

  • Cholesterol
  • Europe
  • Danone SA
  • Raisio Group
  • Unilever PLC
  • R&D Progress Research and Development Brief
  • Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones

" WE USED STATE-OF-THE-ART GENETIC AND STATISTICAL TECHNIQUES TO DEMONSTRATE THAT THE EFFECT OF THE PATIENT' S GENETIC PROFILE WAS ONLY OBSERVED IN THOSE TREATED WITH DALCETRAPIB AND NOT PLACEBO.

  • Cardiology
  • Cardiovascular Disease
  • Cholesterol
  • Hospital
  • Pfizer Inc.
  • 05/24/2016: NEW CHOLESTEROL TREATMENT NOW AVAILABLE FOR CANADIANS

Biobank and GSK to generate genetic sequence data from the ##, ## volunteer participants in the U. K.

  • Cholesterol
  • Therapy
  • United States
  • Company Financials
  • Regeneron Pharmaceuticals, Inc.
  • CAPSTONE THERAPEUTICS FORMS JOINT VENTURE WITH LIPIMETIX
  • DEC 19, 2016: CAPSTONE THERAPEUTICS ANNOUNCES PROFOUND, RAPID LDL CHOLESTEROL REDUCTION IN AEM-28-14 PRIMATE STUDY

FH is a genetic condition that results from the body' s inability to clear low-density lipoprotein (LDL), or bad cholesterol, from the blood.

  • Cholesterol
  • Chronic Disease
  • United States
  • Deals & Alliance
  • LipimetiX Development LLC
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • JD-5037 - DRUG PROFILE

The study patients diagnosis is confirmed both genetically and phenotypically.

  • Cholesterol
  • Obesity
  • Pharmaceutical
  • Statins
  • Esperion Therapeutics, Inc.
  • Apolipoprotein A I (APOA1) - Featured News & Press Releases

The clinical benefit observed in these genetically challenged patients is further evidence supporting HDL therapy in the broader treatment of atherosclerosis.

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • R&D Progress Research and Development Brief
  • R&D Progress Research and Development Brief

ApoE polymorphic alleles are the main genetic determinants of Alzheimer disease.

  • Cardiovascular Disease
  • Cholesterol
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • Clinical Trial profile. 28 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Genetic Variation in Statin Disposition Statin Distribution GDCT## NCT##, ##CRP## Metabolic Disorders Dyslipidemia (Solute Carrier Organic Anion Transporter Family Member ##B## (Liver Specific Organic Anion Transporter ## or LST## or OATPC or Sodium Independent Organic Anion Tra

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Pharmaceutical
  • World
  • Clinical Trial profile. 11 Trial Title
  • Clinical Trial profile. 27 Trial Title

Genetic Effect on Omega ## Fatty Acid Supplementation for the Treatment of Non Alcoholic Fatty Liver Disease in Obese Children and Adolescents Genetic Effect on Omega ## Fatty Acids for the Treatment of Fatty Liver Disease GDCT## NCT##, ##; R##HD## Metabolic Dis

  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

In the future, Genetic Analysis will also operate as a distributor to Biohit Oyj s products and services in Norway.

  • Cholesterol
  • Clinical Trial
  • Infectious Disease
  • United States
  • GlobalData's company
  • CER-001 - DRUG PROFILE
  • APOLIPOPROTEIN A-I (APOA-I) - FEATURED NEWS & PRESS RELEASES

The clinical benefit observed in these genetically challenged patients is further evidence supporting HDL therapy in the broader treatment of atherosclerosis.

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • Licensed From Company
  • Cardiovascular Disease
  • Cholesterol
  • United States
  • World
  • Product Initiative

The results from two genetically-confirmed HoFH patients through ## weeks of treatment showed that gemcabene ## mg decreased mean LDL-C by ##% on top of maximum statin and/ or ezetimibe.

  • Cholesterol
  • Pharmaceutical
  • United States
  • Company
  • Gemphire Therapeutics Inc.

The results from two genetically-confirmed HoFH patients through ## weeks of treatment showed that gemcabene ## mg decreased mean LDL-C by ##% on top of maximum statin and/ or ezetimibe.

  • Cholesterol
  • Therapy
  • United States
  • Company Financials
  • Gemphire Therapeutics Inc.
  • Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results

Development Program and Company Highlights August 2017: December 2017: Planned publication of results from Mendelian randomization studies that genetically validate ACL inhibition, the enzyme target of bempedoic acid.

  • Cholesterol
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Esperion Therapeutics, Inc.
  • R&D Progress Research and Development Brief
  • JUN 11, 2014: CAPSTONE THERAPEUTICS ANNOUNCES INITIATION OF DOSING FOR AEM-28 PHASE 1B/2A HUMAN CLINICAL TRIAL IN REFRACTORY HYPERCHOLESTEROLEMIC SUBJECTS

ApoE polymorphic alleles are the main genetic determinants of Alzheimer disease.

  • Cardiovascular Disease
  • Cholesterol
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • Effect of Multiple Doses of Fenofibrate on the Multiple-Dose Pharmacokinetics of Pravastatin in Healthy Subjects
  • 5. All the trials included are unique trials.

Genetic Individual Variations Drug-supplement Interactions on Intestinal Absorption and Its Genetic Individual Variations GDCT## UMIN##, R## Metabolic Disorders Atherosclerosis, Cardiovascular Risk Factors, Congestive Heart Failure (Heart Failure), Coronary Arter

  • Cholesterol
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Genetic Individual Variations Drug-supplement Interactions on Intestinal Absorption and Its Genetic Individual Variations GDCT## UMIN##, R## Metabolic Disorders Atherosclerosis, Cardiovascular Risk Factors, Congestive Heart Failure (Heart Failure), Coronary Arter

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Research and Development Brief
  • DYSLIPIDEMIA - PIPELINE BY ALNYLAM PHARMACEUTICALS INC, H2 2017

The abstract is entitled as Genetic Target Validation for ATP-Citrate Lyase Inhibition".

  • Cholesterol
  • Chronic Disease
  • United States
  • World
  • Product Initiative
  • LOMITAPIDE MOVED FROM FILED TO MARKETED FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN THE UNITED STATES.

ApoC-III is a genetically validated target for lowering triglycerides.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • Aegerion Pharmaceuticals, Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • Mixed Dyslipidemia - Product Development Milestones

Thirteen patients were enrolled, all of whom had genetically confirmed HoFH, including two subjects who had functionally negative mutations in their LDL receptor (LDL-R) genes.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.